Xphyto Therapeutics Stock Company Profile

Description

XPhyto Therapeutics Corp. operates as a bioscience company in Germany and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, such as depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics, such as rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, COVID-19 LFA screening test, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it engages in the medical cannabis distribution, analytical testing, cannabis extraction, and psychedelic drug formulation businesses. XPhyto Therapeutics Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.